# Korro Bio

the OPERA (Oligonucleotide Promoted Editing of RNA) platform underpins KRRO-110 (in the REWRITE Phase 1/2a study, with FDA orphan-drug designation granted in March 2025) and the newly selected development candidate KRRO-111,…

Source: https://en.bioecon.ru/companies/korro-bio/
Updated: 2026-08-15

- Country: United States
- Ticker: NASDAQ:KRRO

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $85 million private placement (PIPE) financing announced March 9, 2026 | https://www.nasdaq.com/press-release/korro-announces-oversubscribed-85-million-private-placement-2026-03-09 |
| Regulatory approval | Orphan Drug Designation for KRRO-110 from the FDA (March 2025) and the EMA (July 2025) | https://ir.korrobio.com/news-releases/news-release-details/korro-receives-european-medicines-agency-orphan-drug-designation/, https://ir.korrobio.com/news-releases/news-release-details/korro-reports-second-quarter-2025-financial-results-and-provides, https://ir.korrobio.com/news-releases/news-release-details/korro-reports-third-quarter-financial-results-provides-updates/, https://synapse.patsnap.com/drug/a4ccb7d44d6e3790cc6377025558de92, https://www.sec.gov/Archives/edgar/data/1703647/000095017025040755/krro-ex99_1.htm |
| Regulatory approval | FDA Fast Track designation for KRRO-110 | https://ir.korrobio.com/news-releases/news-release-details/korro-reports-third-quarter-financial-results-provides-updates/ |
| Regulatory approval | FDA Investigational New Drug clearance for RNA editing technology | https://ir.korrobio.com/news-releases/news-release-details/korro-reports-third-quarter-financial-results-provides-updates/ |
| Revenue | $5.1 million collaboration revenue for the nine months ended September 30, 2025 | https://ir.korrobio.com/investor-relations/, https://ir.korrobio.com/news-releases/news-release-details/korro-reports-second-quarter-2025-financial-results-and-provides, https://ir.korrobio.com/news-releases/news-release-details/korro-reports-third-quarter-financial-results-provides-updates/ |
| Production site | Headquarters includes 50,453 square feet of office and laboratory space at 60 First Street, Cambridge, Massachusetts | https://archinect.com/firms/release/150120950/tria-designs-innovative-headquarters-for-korro-bio/150456445, https://ir.korrobio.com/static-files/2bd4f199-86d0-4a12-b9a7-9ad29d4bf3e1 |

Independent sources: archinect.com, nasdaq.com, sec.gov, synapse.patsnap.com

## Technologies

- [RNA editing (ADAR) therapeutics](https://en.bioecon.ru/technology/rna-editing-adar-therapeutics/)